Purine metabolites in fibromyalgia syndrome

Clinical Biochemistry

Volumn 46, Issue 1-2, 2013, Pages 37-39

  Fais, A ^a   Cacace, E ^a   Corda, M ^a   Era, B ^a   Peri, M ^a   Utzeri, S ^a   Ruggiero, V ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Fibromyalgia; HPLC; Purine

Indexed keywords

ADENOSINE; GUANOSINE; HYPOXANTHINE; INOSINE; PURINE; URIC ACID; XANTHINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FIBROMYALGIA; HUMAN; LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL; ULTRAVIOLET SPECTROSCOPY;

ADENOSINE; ADULT; AGED; CASE-CONTROL STUDIES; FEMALE; FIBROMYALGIA; HUMANS; HYPOXANTHINE; INOSINE; MIDDLE AGED; PURINES; QUESTIONNAIRES; REFERENCE VALUES; XANTHINE;

EID: 84871737481     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2012.09.009     Document Type: Article

References (16)

1. Cacace E., Ruggiero V., Anedda C., Denotti A., Minerba L., Perpignano G. Quality of life and associated clinical distress in fibromyalgia. Reumatismo 2006, 58(3):226-229.
2. Yunus M.B. Central sensitivity syndromes: a new paradigm and group nosology for fibromyalgia and overlapping conditions, and the related issue of disease versus illness. Semin Arthritis Rheum 2008, 37:339-352.
3. Wolfe F., Smythe H.A., Yunus M.B., et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990, 33:160-172.
4. Burnstock G. Pathophysiology and therapeutic potential of purinergic signaling. Pharmacol Rev 2006, 58:58-86.
5. Yegutkin G.G., Samburski S.S., Jalkanen S. Soluble purine-converting enzymes circulate in human blood and regulate extracellular ATP level via counteracting pyrophosphatase and phosphotransfer reactions. FASEB J 2003, 17:1328-1330.
6. Haskó G., Sitkov M.V., Szabó C. Immunomodulatory and neuroprotective effects of inosine. Trends Pharmacol Sci 2004, 25:152-157.
7. Zöllner N., Reiter S., Gross M., et al. Myoadenylate deaminase deficiency: successful symptomatic therapy by high dose oral administration of ribose. Klin Wochenschr 1986, 64:1281-1290.
8. Bennett R. The Fibromyalgia Impact Questionnaire (FIQ): a review of its development, current version, operating characteristics and uses. Clin Exp Rheumatol 2005, 23:S154-S162.
9. Mease P. Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment. J Rheumatol 2005, 32:6-21.
10. Sawynok X.J.L. Adenosine in the spinal cord and periphery: release and regulation of pain. Prog Neurobiol 2003, 69:313-340.
11. Guieu R., Guedj E., Giorgi R., Dousset A., Tuzzolino V., By Y., et al. High cell surface CD26-associated activities and low plasma adenosine concentration in fibromyalgia. Ann Rheum Dis 2012, 71:1427-1428.
12. Pastor-Anglada M., Casado F.J., Valdés R., Mata J., García-Manteiga J., Molina M. Complex regulation of nucleoside transporter expression in epithelial and immune system cells. Mol Membr Biol 2001, 18:81-85.
13. Urunsak I.F., Gulec U.K., Paydas S., Seydaoglu G., Guze A.B., Vardar M.A. Adenosine deaminase activity in patients with ovarian neoplasms. Arch Gynecol Obstet 2012, 286(1):155-159.
14. Rathbone M.P., Middlemiss P.J., Gysbers J.W., Andrew C., Herman M.A.R., Reed J.K., et al. Trophic effects of purines in neurons and glial cells. Prog Neurobiol 1999, 59:663-690.
15. Ciruela F., Saura C., Canela I., Mallol J., Lluis C., Franco R. Adenosine deaminase affects ligand-induced signaling by interacting with cell surface adenosine receptors. FEBS Lett 1996, 380:219-223.
16. Guinzberg R., Cortés D., Díaz-Cruz A., Riveros-Rosas H., Villalobos-Molina R., Piña E. Inosine released after hypoxia activates hepatic glucose liberation through A3 adenosine receptors. Am J Physiol Endocrinol Metab 2006, 290:940-951.